HK Stock Market Move | INNOVENT BIO(01801) rises more than 5%, IBI363 (PD-1/IL-2-bias) and other pipeline products will debut at 2025 ASCO.

INNOVENT BIO (01801) rose more than 5%, up 5.05% as of the release, at HKD 54.05, with a turnover of HKD 1.591 billion. On the news front, on April 24th, INNOVENT BIO announced that it will present a series of clinical data on its innovative pipeline for oncology at the American Society of Clinical Oncology (ASCO) annual meeting. Among them, IBI363 (PD-1/IL-2-bias) has oral reports on clinical studies in melanoma, colon cancer, and non-small cell lung cancer, and IBI343 (CLDN18.2 ADC) has research on pancreatic cancer. Drugs like sintilimab have also shown results in studies on classical Hodgkin lymphoma, locally advanced colorectal cancer, and nasopharyngeal carcinoma. This year's ASCO annual meeting will be held in Chicago, USA from May 30 to June 3, 2025. BOCOM INTL previously pointed out that the company has strong certainty in long-term growth: after achieving positive non-IFRS EBITDA and net profit in 2024, the company continues to guide for a revenue of 20 billion yuan in 2027, and sets a new goal of pushing 5 pipeline assets into global multi-center phase III clinical trials by 2030. In the commercialization and late-stage pipeline, potential blockbuster single products like masitinib, PD-1/IL-2, and CLDN18.2 ADC are the recent focus of the company's research and development efforts, with multiple data readouts to be anticipated in the next 12 months. The bank recommends focusing on the PoC data of PD-1/IL-2 on various cold tumors and multiple phase III data of masitinib for diabetes/weight loss.